IDEAYA Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
IDEAYA Biosciences, Inc. (IDYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 667.07 thousand shares for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-24.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2020-03-24
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-12-31 was 134.50K shares, a 1.48% decline year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-09-30 was 82.10K shares, a 32.04% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-12-31 was 136.52K shares.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-09-30 was 62.18K shares.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 667.07K shares, a 52.95% decline from fiscal 2018.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 1.42M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2019-12-31 | 134.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | 216.60K shares derived: sum of 2 quarters · filed 2020-03-24 | 667.07K shares 10-K · filed 2020-03-24 | |
| 2019-09-30 | 82.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | 532.57K shares 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | 450.47K shares 10-Q · filed 2019-08-12 | |||
| 2018-12-31 | 136.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | 198.70K shares derived: sum of 2 quarters · filed 2020-03-24 | 1.42M shares 10-K · filed 2020-03-24 | |
| 2018-09-30 | 62.18K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | 1.28M shares 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | 1.22M shares 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |